You are here:Home-Research Areas-Other Indications-Steatohepatitis

Request The Product List ofSteatohepatitis Steatohepatitis

Cat. No. Product Name CAS No. Information
PC-61592

IVA-337

927961-18-0

IVA-337 (Lanifibranor, IVA337)) is a potent, pan PPAR agonist with EC50 of 0.92 uM, 0.53 uM and 0.18 uM for human PPARα, PPARδ and PPARγ respectively; reduces skin fibrosis in the mouse, and suppresses inflammation in vivo.

Steatohepatitis

Phase 2 Clinical

PC-61473

BI 1467335

1478364-68-9

BI 1467335 (PXS-4728A, PXS-4728) is a potent, selective, orally active SSAO/VAP-1 (AOC3) inhibitor with IC50 of 5 nM; displays >500-fold selective for VAP-1/SSAO over all the related human amine oxidases; diminishes leukocyte rolling and adherence induced by CXCL1/KC, also inhibits the migration of neutrophils to the lungs in response to LPS, Klebsiella pneumoniae lung infection and CLP induced sepsis.

Steatohepatitis

Phase 2 Clinical

PC-61377

Firsocostat

1434635-54-7

Firsocostat (ND-630, NDI-010976, GS-0976) is a highly potent, selective inhibitor of acetyl-CoA carboxylase (ACC) with IC50 of 2.1 and 6.1 nM for isozymes ACC1 and ACC2, respectively; displays no activity against 101 enzymes, receptors, growth factors, transporters, and ion channels at 10 uM; reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia in DIO mice.

Steatohepatitis

Phase 2 Clinical

PC-61368

Cilofexor

1418274-28-8

Cilofexor (GS-9674, GS9674, PX-104) is a novel specific, non-steroidal farnesoid X receptor (FXR) agonist that reduces liver fibrosis and ameliorates portal hypertension in rat NASH models.

Steatohepatitis

Phase 2 Clinical

PC-60056

Tropifexor

1383816-29-2

Tropifexor (LJN-452, LJN452) is a novel highly potent, selective, orally acitive FXR full agonist with EC50 of 0.26 nM; shows no significant off-target activity (>10,000-fold selectivity for FXR) in a panel of targets, including TGR5 (>10 uM); demonstratesin vivo activity in rodent PD models, and shows potential for treatment of cholestatic liver diseases and NASH.

Steatohepatitis

Phase 2 Clinical

PC-42920

MGL-3196

920509-32-6

MGL-3196 (VIA-3196, Resmetirom) is a potent and highly selective agonist of THR-β (Thyroid Hormone Receptor β) with EC50 of 0.21 uM; shows 28-fold selectivity for THR-β over THR-α in a functional assay; exhibits an excellent safety profile and orally bioactive.

Steatohepatitis

Phase 2 Clinical

PC-45565

Selonsertib

1448428-04-3

Selonsertib (GS-4997) is a highly selective and potent, ATP-competetive inhibitor of ASK1 (Apoptosis Signal-regulating Kinase 1, MAP3K5) with potential anti-inflammatory, antineoplastic and anti-fibrotic activities; orally bioavailable.

Steatohepatitis

Phase 3 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com